24 research outputs found
Mecanismos intracelulares involucrados en la colestasis por estrógenos : rol del receptor de estrógenos
El estradiol 17ß-D-glucurónido (E17G) induce colestasis aguda en la rata con
internalización endocítica de los transportadores canaliculares, Abcb11 y Abcc2. Las
vías de señalización de la proteína quinasa clásica (PKCc) y las vías de señalización de
PI3K juegan roles complementarios en la colestasis por E17G, también se ha reportado
la participación de la vía GPR30/AC/PKA. Ya que el estradiol no conjugado es capaz
de activar estas vías de señalización a través de la activación del receptor de estrógeno
alfa (REα), en este trabajo de Tesis se postula como hipótesis la participación de REα en
las manifestaciones colestásicas del E17G en el modelo de Hígado Aislado y Perfundido
de rata (HAPR) como así también en modelos de cultivos primario de hepatocitos de
rata. En el modelo de HAPR y en cultivo primario de hepatocitos, el E17G activó el
REα. En HAPR, E17G disminuyó el flujo biliar y las excreciones de dinitrofenilglutation,
y taurocolato (sustratos específicos de Abcc2 y Abcb11, respectivamente) en
aproximadamente 60 %; la pre-administración de ICI (inhibidor de REα) previno en
forma casi completa estas disminuciones. En el modelo de duplas aisladas de
hepatocitos de rata (DAHR), un modelo polarizado de hepatocitos en cultivo, el
tratamiento con E17G disminuyó la acumulación vacuolar canalicular de colil-glicilamido
fluoresceína (sustrato de Abcb11) con un CI50 de 91±1 μM. El tratamiento con
ICI aumentó la CI50 a 102±1 μM, y similarmente previno la disminución de la
acumulación vacuolar canalicular del sustrato de Abcc2, glutatión-metil fluoresceína,
con una CI50 de 104±1μM sin ICI y un CI50 de 164±2 μM en presencia del inhibidor.
El inhibidor ICI también previno completamente la internalización endocítica de los
transportadores canaliculares Abcb11 y Abcc2.
La participación de REα se confirmó a través del uso de knock-down del REα en
cultivo primario de hepatocitos en configuración “sándwich” (HRCS) donde se observó
que la disminución de la expresión de REα previno la internalización de ambos
transportadores cuando las células fueron tratadas con E17G.
En el modelo de DAHR, la protección de ICI tuvo un efecto sumatorio cuando fue
probado conjuntamente con Wortmanina, un inhibidor de PI3K pero no se observó un
efecto sumatorio con el inhibidor Gö6976, un inhibidor de PKCc; sugiriendo que REα
forma parte de la vía de señalización de PKCc pero no de la vía de señalización de
PI3K. Un análisis más detallado de las activaciones REα y PKCc inducida por E17G,
demostró que ICI no afecta a la activación PKCc mientras que Gö6976 impidió la
activación de REα, lo que indica que la activación de PKCc (evaluada a través de la
activación de PKCα) precede a la activación de REα. Por otro lado, también se observó
mediante la técnica de western blot en cultivo primario de hepatocitos que la activación
de REα ocurriría independientemente de la vía GPR30/AC/PKA y que probablemente la
fosforilación de sustratos de PKA (o su mantenimiento en estado fosforilado) depende
de la activación de REα.
Conclusión: el REα está implicado en la falla secretora biliar inducida por E17G y su
activación ocurre luego de la activación de PKCc. REα activado participaría en cascadas
de señalización que conducen a la desinserción como por ejemplo las derivadas de la
activación de PKA.Fil: Barosso, Ismael R. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Fisiología Experimental (IFISE-CONICET); Argentina
Mitogen-activated protein kinases are involved in hepatocanalicular dysfunction and cholestasis induced by oxidative stress
In previous studies, we showed that the pro-oxidant model agent tert-butyl hydroperoxide (tBuOOH) induces alterations in hepatocanalicular secretory function by activating Ca2+-dependent protein kinase C isoforms (cPKC), via F-actin disorganization followed by endocytic internalization of canalicular transporters relevant to bile formation (Mrp2, Bsep). Since mitogen-activated protein kinases (MAPKs) may be downstream effectors of cPKC, we investigated here the involvement of the MAPKs of the ERK1/2, JNK1/2, and p38MAPK types in these deleterious effects. tBuOOH (100 µM, 15 min) increased the proportion of the active, phosphorylated forms of ERK1/2, JNK1/2, and p38MAPK, and panspecific PKC inhibition with bisindolylmaleimide-1 (100 nM) or selective cPKC inhibition with Gö6976 (1 μM) prevented the latter two events. In isolated rat hepatocyte couplets, tBuOOH (100 µM, 15 min) decreased the canalicular vacuolar accumulation of the fluorescent Bsep and Mrp2 substrates, cholylglycylamido fluorescein, and glutathione-methylfluorescein, respectively, and selective inhibitors of ERK1/2 (PD098059), JNK1/2 (SP600125), and p38MAPK (SB203580) partially prevented these alterations. In in situ perfused rat livers, these three MAPK inhibitors prevented tBuOOH (75 µM)-induced impairment of bile flow and the decrease in the biliary output of the Bsep and Mrp2 substrates, taurocholate, and dinitrophenyl-S-glutathione, respectively. The changes in Bsep/Mrp2 and F-actin localization induced by tBuOOH, as assessed by (immuno)fluorescence staining followed by analysis of confocal images, were prevented total or partially by the MAPK inhibitors. We concluded that MAPKs of the ERK1/2, JNK1/2, and p38MAPK types are all involved in cholestasis induced by oxidative stress, by promoting F-actin rearrangement and further endocytic internalization of canalicular transporters critical for bile formation.Fil: Toledo, Flavia D. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Fisiología Experimental (IFISE-CONICET); Argentina.Fil: Basiglio, Cecilia Lorena. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Fisiología Experimental (IFISE-CONICET); Argentina.Fil: Barosso, Ismael R. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Fisiología Experimental (IFISE-CONICET); Argentina.Fil: Boaglio, Andrea C. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Fisiología Experimental (IFISE-CONICET); Argentina.Fil: Zucchetti, Andrés E. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Fisiología Experimental (IFISE-CONICET); Argentina.Fil: Sanchez Pozzi, Enrique J. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Fisiología Experimental (IFISE-CONICET); Argentina.Fil: Roma, Marcelo Gabriel. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Fisiología Experimental (IFISE-CONICET); Argentina
G-protein-coupled receptor 30/adenylyl cyclase/protein kinase A pathway is involved in estradiol 17ß-D-glucuronide-induced cholestasis
Estradiol-17ß-D-glucuronide (E17G) activates different signaling pathways (e.g., Ca21-
dependent protein kinase C, phosphoinositide 3-kinase/protein kinase B, mitogenactivated
protein kinases [MAPKs] p38 and extracellular signal-related kinase 1/2, and
estrogen receptor alpha) that lead to acute cholestasis in rat liver with retrieval of the
canalicular transporters, bile salt export pump (Abcb11) and multidrug resistanceassociated
protein 2 (Abcc2). E17G shares with nonconjugated estradiol the capacity to
activate these pathways. G-protein-coupled receptor 30 (GPR30) is a receptor implicated
in nongenomic effects of estradiol, and the aim of this study was to analyze the potential
role of this receptor and its downstream effectors in E17G-induced cholestasis. In
vitro, GPR30 inhibition by G15 or its knockdown with small interfering RNA strongly
prevented E17G-induced impairment of canalicular transporter function and localization.
E17G increased cyclic adenosine monophosphate (cAMP) levels, and this increase
was blocked by G15, linking GPR30 to adenylyl cyclase (AC). Moreover, AC inhibition
totally prevented E17G insult. E17G also increased protein kinase A (PKA) activity,
which was blocked by G15 and AC inhibitors, connecting the links of the pathway,
GPR30-AC-PKA. PKA inhibition prevented E17G-induced cholestasis, whereas exchange
protein activated directly by cyclic nucleotide/MAPK kinase, another cAMP downstream
effector, was not implicated in cAMP cholestatic action. In the perfused rat liver model,
inhibition of the GPR30-AC-PKA pathway totally prevented E17G-induced alteration in
Abcb11 and Abcc2 function and localization. Conclusion: In conclusion, activation of
GPR30-AC-PKA is a key factor in the alteration of canalicular transporter function and
localization induced by E17G. Interaction of E17G with GPR30 may be the first event
in the cascade of signaling activation.Fil: Zucchetti, Andrés E. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Fisiología Experimental (IFISE-CONICET); Argentina.Fil: Barosso, Ismael R. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Fisiología Experimental (IFISE-CONICET); Argentina.Fil: Boaglio, Andrea C. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Fisiología Experimental (IFISE-CONICET); Argentina.Fil: Basiglio, Cecilia Lorena. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Fisiología Experimental (IFISE-CONICET); Argentina.Fil: Miszczuk, Gisel Sabrina. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Fisiología Experimental (IFISE-CONICET); Argentina.Fil: Larocca, María Cecilia. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Fisiología Experimental (IFISE-CONICET); ArgentinaFil: Ruiz, M. Laura. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Fisiología Experimental (IFISE-CONICET); Argentina.Fil: Davio, Carlos A. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Farmacología. Laboratorio de Farmacología de Receptores; Argentina.Fil: Roma, Marcelo Gabriel. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Fisiología Experimental (IFISE-CONICET); Argentina.Fil: Crocenzi, Fernando A. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Fisiología Experimental (IFISE-CONICET); Argentina.Fil: Sánchez Pozzi, Enrique J. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Fisiología Experimental (IFISE-CONICET); Argentina
Prevention of estradiol 17β-d-glucuronide–induced canalicular transporter internalization by hormonal modulation of cAMP in rat hepatocytes
Glucagon- and salbutamol-derived cAMP prevents estrogen-induced alteration of canalicular transporter localization and function via different pathways. Glucagon-derived protection depends on PKA activation, whereas salbutamol protection is exerted through a pathway that depends on Epac/MEK and microtubules
Schematic representation of the signalling events involved in E<sub>2</sub>17G-induced cholestasis by endocytic internalization and further retention of canalicular transporters relevant to bile formation (Bsep, Mrp2).
<p>p38, acting downstream of cPKC, triggers endocytic internalization of the apical carriers presumably towards apical early endosomes (AEE), the first intracellular endosomal compartment receiving internalized proteins from the apical membrane, in a microtubule-independent manner (solid arrow). These transporters traffic to, and accumulate into, apical recycling endosomes (ARE), from where they can be retargeted to the apical membrane during the recovery of the cholestatic process, in a microtubule-dependent manner (dashed arrows). Activation of the PI3K/Akt/ERK1/2 signalling pathway halts this latter process, thus explaining the increased colocalization of Bsep/Mrp2 with Rab11a, an ARE marker. This prolongs the cholestatic effect of E<sub>2</sub>17G by impeding the fast, spontaneous retargeting of intracellular transporters that would lead to a rapid recovery from the cholestatic injury.</p
Effect of inhibition of p38 or ERK1/2, and coinhibition of cPKC-ERK1/2, PI3K-p38, or p38-ERK1/2 on E<sub>2</sub>17G-induced retrieval of Bsep and Mrp2 in IRHCs.
<p>The upper panels show representative confocal immunofluorescence images of the localization of Bsep and Mrp2 in DMSO-treated (control) or E<sub>2</sub>17G (200 µM)-treated IRHCs, with or without the p38 inhibitor SB203580 (SB; 1 µM) or the ERK1/2 inhibitor PD98059 (PD; 5 µM), in combination or not with the cPKC inhibitor Gö6976 (Gö; 1 µM) or PI3K inhibitor wortmanin (WM; 100 nM). The lower panels show the densitometric analysis of the fluorescence intensity along a line (8 µm) perpendicular to the center of the canalicular vacuole (from +4 to −4 µm). The statistical analysis of the profiles of fluorescence showed a significant change in the E<sub>2</sub>17G-treated group (P<0.05; number of analyzed canalicular vacuoles >10), but this reverted to normal in the E<sub>2</sub>17G-SB, E<sub>2</sub>17G-PD, E<sub>2</sub>17G-PD-SB, E<sub>2</sub>17G-Gö-PD and E<sub>2</sub>17G-WM-SB groups for Bsep and Mrp2.</p
Effect of E<sub>2</sub>17G on colocalization of Rab11a with Mrp2 or Bsep in IRHCs.
<p>Immunofluorescence confocal images showing staining of Mrp2 or Bsep (green) and Rab11a (red) in IRHCs treated with DMSO (control), the ERK1/2 inhibitor PD98059 (PD; 5 µM), the p38 inhibitor SB203580 (SB; 1 µM), or both inhibitors together. Colocalization of Rab11a with Mrp2 or Bsep in the E<sub>2</sub>17G-treated group is indicated by orange-yellow fluorescence in merged images. Insets depict F-actin staining, which was used to demarcate the limits of the canalicular vacuoles.</p
Effect of the inhibition of p38, ERK1/2 and JNK1/2, or the coinhibition of cPKC-ERK1/2, PI3K-p38, or p38-ERK1/2, on E<sub>2</sub>17G-induced impairment of the canalicular accumulation of the Bsep and Mrp2 fluorescent substrates in IRHCs.
<p>IRHCs were incubated with E<sub>2</sub>17G (200 µM, 20 min) (or DMSO in controls), with or without pretreatment for 15 min with the JNK1/2 inhibitor SP600125 (1 µM), the ERK1/2 inhibitor PD98059 (PD; 5 µM), and/or the p38 inhibitor SB203580 (SB; 1 µM), together or not with the cPKC inhibitor Gö6976 (Gö; 1 µM) or PI3K inhibitor wortmanin (WM; 100 nM). Canalicular accumulation CGamF (Bsep substrate, panel A) and GS-MF (Mrp2 substrate, panel B) was determined as the percentage of couplets displaying visible fluorescence in their canalicular vacuoles from a total of at least 200 couplets per preparation. The results are expressed as percentages of the control group and are shown as mean ± SEM (<i>n</i> = 3–4). *P<0.05 <i>vs.</i> E<sub>2</sub>17G, and <sup>#</sup>P<0.05 <i>vs.</i> E<sub>2</sub>17G-WM, E<sub>2</sub>17G-Gö, E<sub>2</sub>17G-PD or E<sub>2</sub>17G-SB.</p
E<sub>2</sub>17G activates the MAPK signalling pathway.
<p><i>(A)</i> left panel: representative Western blottings of phospho (p)-p38, p-ERK1/2, p-JNK1/2 and total forms of all these MAPK types were obtained from whole cellular lysates of primary-cultured rat hepatocytes incubated with E<sub>2</sub>17G (200 µM) for 10 to 60 min, or with E<sub>2</sub>17G (200 µM) for 20 min in cells pretreated with the PI3K inhibitor wortmanin (WM, 100 nM) or with the cPKC inhibitor Gö6976 (Gö, 1 µM) for 15 min. <i>A</i> (right panel), and <i>B</i> and <i>C panels</i> show phosphorylation status of all MAPK types evaluated (calculated as the p-MAPK to total MAPK ratio for each experimental condition). An arbitrary value of 100 was assigned to the band of highest densitometric intensity in every Western blot before the ratio was calculated. The results are shown as mean ± SEM (<i>n</i> = 5). *P<0.05 <i>vs.</i> control (cells treated only with DMSO), and <sup>#</sup>P<0.05 <i>vs.</i> E<sub>2</sub>17G (20 min).</p
Sequential Activation of Classic PKC and Estrogen Receptor α Is Involved in Estradiol 17ß-D-Glucuronide-Induced Cholestasis
<div><p>Estradiol 17ß-d-glucuronide (E17G) induces acute cholestasis in rat with endocytic internalization of the canalicular transporters bile salt export pump (Abcb11) and multidrug resistance-associated protein 2 (Abcc2). Classical protein kinase C (cPKC) and PI3K pathways play complementary roles in E17G cholestasis. Since non-conjugated estradiol is capable of activating these pathways <em>via</em> estrogen receptor alpha (ERα), we assessed the participation of this receptor in the cholestatic manifestations of estradiol glucuronidated-metabolite E17G in perfused rat liver (PRL) and in isolated rat hepatocyte couplets (IRHC). In both models, E17G activated ERα. In PRL, E17G maximally decreased bile flow, and the excretions of dinitrophenyl-glutathione, and taurocholate (Abcc2 and Abcb11 substrates, respectively) by 60% approximately; preadministration of ICI 182,780 (ICI, ERα inhibitor) almost totally prevented these decreases. In IRHC, E17G decreased the canalicular vacuolar accumulation of cholyl-glycylamido-fluorescein (Abcb11 substrate) with an IC50 of 91±1 µM. ICI increased the IC50 to 184±1 µM, and similarly prevented the decrease in the canalicular vacuolar accumulation of the Abcc2 substrate, glutathione-methylfluorescein. ICI also completely prevented E17G-induced delocalization of Abcb11 and Abcc2 from the canalicular membrane, both in PRL and IRHC. The role of ERα in canalicular transporter internalization induced by E17G was confirmed in ERα-knocked-down hepatocytes cultured in collagen sandwich. In IRHC, the protection of ICI was additive to that produced by PI3K inhibitor wortmannin but not with that produced by cPKC inhibitor Gö6976, suggesting that ERα shared the signaling pathway of cPKC but not that of PI3K. Further analysis of ERα and cPKC activations induced by E17G, demonstrated that ICI did not affect cPKC activation whereas Gö6976 prevented that of ERα, indicating that cPKC activation precedes that of ERα. Conclusion: ERα is involved in the biliary secretory failure induced by E17G and its activation follows that of cPKC.</p> </div